These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New FDA breakthrough-drug category--implications for patients. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173 [No Abstract] [Full Text] [Related]
3. New FDA breakthrough-drug category--implications for patients. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2014 Jul; 371(1):89-90. PubMed ID: 24988576 [No Abstract] [Full Text] [Related]
4. New FDA breakthrough-drug category--implications for patients. McClellan M; Sigal E N Engl J Med; 2014 Jul; 371(1):87-8. PubMed ID: 24988577 [No Abstract] [Full Text] [Related]
5. New FDA breakthrough-drug category--implications for patients. Murray BE N Engl J Med; 2014 Jul; 371(1):88. PubMed ID: 24988578 [No Abstract] [Full Text] [Related]
6. New FDA breakthrough-drug category--implications for patients. Velleca M N Engl J Med; 2014 Jul; 371(1):88-9. PubMed ID: 24988579 [No Abstract] [Full Text] [Related]
7. New FDA breakthrough-drug category--implications for patients. Ricart AD N Engl J Med; 2014 Jul; 371(1):89. PubMed ID: 24988580 [No Abstract] [Full Text] [Related]
8. New office and new leader aim to streamline FDA cancer drug review process. Twombly R J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036 [No Abstract] [Full Text] [Related]
9. FDA treads delicate line between safety and speed. Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195 [No Abstract] [Full Text] [Related]
10. Internal reform at the FDA. Stein GC Am J Health Syst Pharm; 1996 Sep; 53(17):2087-9. PubMed ID: 8870898 [No Abstract] [Full Text] [Related]
11. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
12. Faster is not always better. Liebman M Clin J Oncol Nurs; 1998 Jan; 2(1):3. PubMed ID: 9481249 [No Abstract] [Full Text] [Related]
13. Will politics sidetrack FDA reform? Gatty B Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736 [No Abstract] [Full Text] [Related]
14. Perspectives. Approval process a moving target in FDA reform hearings. Rhein R Faulkner Grays Med Health; 1996 Feb; 50(8):suppl 1-4. PubMed ID: 10154482 [No Abstract] [Full Text] [Related]
15. FDA reform plan edges closer to realisation. Marx V Lancet; 2012 Jun; 379(9832):2135. PubMed ID: 22690392 [No Abstract] [Full Text] [Related]
16. Food and drug administration expanded access to treatment: implications for oncology patients. Freedman RS; Markman M Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587 [No Abstract] [Full Text] [Related]
17. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094 [No Abstract] [Full Text] [Related]
18. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward. Bateman-House A; Robertson CT JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821 [No Abstract] [Full Text] [Related]
19. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
20. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval? Khozin S; Liu K; Jarow JP; Pazdur R Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722 [No Abstract] [Full Text] [Related] [Next] [New Search]